OvidRx - Mittel gegen das Angelman-Snydrom?

Ovid Therapeutics hat ein Mittel in Phase 2 gegen das sogenannte Angelman-Syndrom

http://www.ovidrx.com/our-pipeline/

Angelman-Syndrom

https://www.youtube.com/watch?v=h4gykdYj1LQ

Aktuell: 10,94EUR +1,31EUR +13,59%  

 

 

http://www.analystratings.com/articles/...g-on-ovid-therapeutics-inc/  

https://endpts.com/...cy-data-for-their-phii-angelman-syndrome-trial/  

Offering

• 12,5 Mio. Aktie zu je 2$ ~25 Mio. $
  

http://investors.ovidrx.com/...&p=irol-newsArticle&ID=2388165

 

OV101

https://www.statnews.com/2019/05/06/...mental-drug-ovid-therapeutics/

 

https://www.nasdaq.com/de/symbol/ovid/real-time  

https://www.nasdaq.com/de/symbol/ovid/real-time  

Ovid meldet Zahlen für Q1/19

• keine Umsätze
  
• Verlust 14 Mio. $
  
• Cash 60 Mio. $
  
• MK 71 Mio. $
  

http://investors.ovidrx.com/news-releases/...r-2019-financial-results

 

https://www.analystratings.com/articles/...eives-a-buy-from-cowen-co/


May 12, 2019   Best Performing Analysts, Healthcare, Top Market News   0 Comments
Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.
By Carrie Williams

[Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.] In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ovid Therapeutics Inc (OVID – Research Report). The company’s shares closed on Friday at $1.71, close to its 52-week low of $1.64.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 52.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Ovid Therapeutics Inc is a Strong Buy with an average price target of $13.40, implying a 683.6% upside from current levels. In a report issued on May 7, Ladenburg also maintained a Buy rating on the stock with a $27 price target.  

https://www.fiercebiotech.com/biotech/...-ov101-for-angelman-syndrome  

 

 

https://www.analystratings.com/articles/...ed-its-third-buy-in-a-row/  

 

+100% seit meinem letzten Posting #12
https://seekingalpha.com/news/...-7-percent-positive-soticlestat-data  

 

https://www.benzinga.com/news/earnings/19/10/...peutics-shares-plunge  

Public Offerings angekündigt - Gesamtvolumen ca. ~33 Mio. $

• 9 Mio. neue Aktien zu je 2,50$ = ~ 22,5 Mio. $
  
• + Option auf weitere 15%
  

http://investors.ovidrx.com/news-releases/...g-325-million-securities

 

 

https://www.analystratings.com/articles/...on-ovid-therapeutics-ovid/  

Mal sehen, mal auf die Lauer legen....  

https://old.nasdaq.com/de/symbol/ovid/real-time  

https://xconomy.com/new-york/2019/11/18/...vartiss-tardio-to-c-suite/

Außerdem scheinen sie nächstes Jahr kein Geld zu brauchen (siehe letzter Abschnitt):



One activity the company doesn’t plan to focus on next year is financing. Ovid is set until “well into 2021” when it comes to capital, Levin says.